NHS England now offers the "Trojan horse" therapy, belantamab mafodotin (Blenrep) for patients with multiple myeloma.

Recent collaborations highlight a growing interest in building a multiomics-based understanding of health and disease.

GSK PLC GSK shares dropped 2.45% to £15.12 Friday, on what proved to be an all-around poor trading session for the stock ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

The partnership includes support for the design of the Phase III trial and assistance in securing external funding.

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Patients with eosinophilic granulomatosis with polyangiitis experienced significant improvements in a variety of outcomes ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its ...

This Original Lifetime Movie, "Pretty Hurts," airs June 28, at 8 p.m.

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

GSK has licensed its shigella vaccine candidate to Bharat Biotech. The Big Pharma, which has vowed to help Bharat with trial ...